Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2014 Feb 18;23(5):515–525. doi: 10.1002/pds.3595

Figure 2.

Figure 2

Distribution of heparin dose in subgroups with different risk factors for bleeding: Panel A) patients with low bleeding risk (no history of gastrointestinal bleeding, hemorrhagic stroke, or thrombocytopenia); Panel B) patients with only a history of gastrointestinal bleeding; Panel C) patients with only a history of hemorrhagic stroke; Panel D) patients with only thrombocytopenia (platelet count <150,000/μL within 90 days of heparin administration); Panel E) Patients with more than one risk factor for bleeding. Subgroups are mutually exclusive.